Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2017 Feb;83(2):432-433.
doi: 10.1111/bcp.13122. Epub 2016 Sep 29.

Endpoints in strategies to reduce polypharmacy

Andrés Gaviria-Mendoza  1 , Jorge Enrique Machado-Alba  1 , Juan Pablo Castaño-Montoya  1 , Manuel Enrique Machado-Duque  1 , Claudia Giraldo-Giraldo  1
Affiliations
Comment

Endpoints in strategies to reduce polypharmacy

Andrés Gaviria-Mendoza et al. Br J Clin Pharmacol. 2017 Feb.
No abstract available

PubMed Disclaimer

Comment in

Comment on

References

    1. Cojutti P, Arnoldo L, Cattani G, Brusaferro S, Pea F. Polytherapy and the risk of potentially inappropriate prescriptions (PIPs) among elderly and very elderly patients in three different settings (hospital, community, long‐term care facilities) of the Friuli Venezia Giulia region, Italy: are the very elderly at higher risk of PIPs? Pharmacoepidemiol Drug Saf 2016; 25: 1070–1078. - PubMed
    1. Corsonello A, Pedone C, Incalzi RA. Age‐related pharmacokinetic and pharmacodynamic changes and related risk of adverse drug reactions. Curr Med Chem 2010; 17: 571–584. - PubMed
    1. Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf 2014; 13: 57–65. - PMC - PubMed
    1. Johansson T, Abuzahra ME, Keller S, Mann E, Faller B, Sommerauer C, et al. Impact of strategies to reduce polypharmacy on clinically relevant endpoints: a systematic review and meta‐analysis. Br J Clin Pharmacol 2016; 82: 532–548. - PMC - PubMed
    1. Portilla A, Torres D, Machado‐Duque ME, Machado‐Alba JE. Intervención en la prescripción de la combinación de inhibidor de la enzima convertidora de angiotensina (IECA) y bloqueador del receptor de angiotensina II (BRA‐II. Aten Primaria 2016; 48: 272–274. - PMC - PubMed

LinkOut - more resources